Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Unknown 2Recruiting 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 18OTHER 7OTHER_GOV 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Thoracic 41Gastrointestinal 18Head & Neck 17Tumor-Agnostic 7Breast 6Genitourinary 4CNS 4Sarcoma 2Dermatologic 2Classical hematology 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Carcinoma, Squamous Cell 2

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × Afatinib × Tumor-Agnostic × Clear all
NCT04410653 2024-04-05

Afatinib in Advanced NRG1-Rearranged Malignancies

German Cancer Research Center

Phase 2 Completed
3 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT04533321 2020-08-31

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

National University Hospital, Singapore

Phase 2 Unknown
20 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT03652233 2019-06-20

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡